Therefore, PCA’s therapeutic potential in DKD stems from a dual-front attack: its ability to precisely target the miRNA-10b/ABCA1 axis to resolve cellular lipotoxicity and its capacity to concurrently improve systemic glycemic control and suppress renal inflammation. The gene discussed is ABCA1; the disease is diabetic kidney disease.